By Chad Terhune and Dan Levine (Reuters) -One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy ...

BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

An analyst's downbeat new take on Summit Therapeutics ( SMMT -11.32%) pushed its stock downward on Hump Day. At the end of ...

The stock's fall snapped a three-day winning streak.

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

However, considering it hovered near bear market territory a few weeks ago, things aren't so bad. Stocks might not be out of ...

(Reuters) -U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it ...